Drug Profile
Vonafexor - ENYO Pharma
Alternative Names: EYP 001; EYP001a; PXL 007Latest Information Update: 16 Jan 2024
Price :
$50
*
At a glance
- Originator Poxel
- Developer ENYO Pharma; Poxel; PRA Health Sciences
- Class Antivirals; Benzopyrans; Carboxylic acids; Chlorobenzenes; Hepatoprotectants; Piperazines; Small molecules; Sulfones
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Hepatitis B; Kidney disorders; Non-alcoholic steatohepatitis
Most Recent Events
- 16 Jan 2024 Phase-II clinical trials in Kidney disorders (unspecified route) (Enyo Pharma pipeline, January 2023)
- 03 Jan 2024 US FDA approves IND application for Vonafexor in Alport syndrome
- 03 Jan 2024 Pharmacodynamics data from a preclinical trial in Alport syndrome and Chronic kidney disease released by ENYO Pharma